Objective: The purpose of this study was to compare the clinical efficacy and safety of cefmetazole given by IV push with that of parenterally administered cefoxitin for the treatment of endometritis following cesarean delivery.
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Cesarean delivery, cephamycins, cephalosporins, bacteria major cause of maternal morbidity during the postpartum period is endometritis. Cesarean delivery is the most important clinical factor for the development of endometritis. The incidence of endometritis following cesarean delivery has ranged from 5 to 85%. Endometritis is polymicrobial [2] [3] [4] in nature; therefore, antibiotic coverage often requires multiple agents to achieve adequate coverage. In an attempt to simplify the therapy, some investigators s'6 have evaluated monotherapy with cephamycins.
Cephamycins are a group of parenterally administered cephalosporins characterized by an alphamethoxy group at position 7. This configuration enables the cephamycins to be effective against a remarkable number of aerobic and anaerobic bacte-ria. Studies comparing different cephamycins for prophylaxis and therapy have yielded similar effi- 7--9 cacy and cure rates.
With most regimens reporting similar cure rates for different cephamycins, the focus has shifted to the cost and ease of administration. A drug with a longer half-life requiring less frequent administration can result in considerable savings.
1 '1 Cefmetazole, a new cephamycin, has a longer halflife than cefoxitin. It has also been demonstrated to be more active than cefoxitin against isolated species. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] With this in mind, we initiated this randomized, controlled trial to compare the clinical effectiveness and safety of cefmetazole vs. cefoxitin in the treatment of endometritis after cesarean delivery.
MATERIALS AND METHODS

Patients
The patients eligible for enrollment were hospitalized women, 16 In summary, in the evaluation of an antibiotic in this cost-containment era, the cost effectiveness of treatment, including the economic impact of making such changes, must be considered. This evaluation can be simplified by assigning weights to major criteria, i.e., spectrum of activity, pharmacokinetics, frequency and ease of administration, adverse reactions, costs, and stability. Under this analysis, cefmetazole received a much higher score than cefoxitin did. 23 
